Heron Therapeutics Inc (NASDAQ:HRTX) CEO Barry D. Quart sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $24.75, for a total transaction of $2,475,000.00. Following the sale, the chief executive officer now owns 167,993 shares of the company’s stock, valued at approximately $4,157,826.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Heron Therapeutics Inc (HRTX) traded down $0.40 on Friday, reaching $21.50. 2,575,128 shares of the company’s stock traded hands, compared to its average volume of 1,017,152. The firm has a market cap of $1,415.80, a PE ratio of -5.87 and a beta of 1.87. Heron Therapeutics Inc has a 12 month low of $12.70 and a 12 month high of $25.35.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.29). The firm had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.00 million. Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. sell-side analysts forecast that Heron Therapeutics Inc will post -2.56 EPS for the current fiscal year.
HRTX has been the topic of a number of recent research reports. ValuEngine cut shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Monday, January 15th. Leerink Swann initiated coverage on shares of Heron Therapeutics in a report on Tuesday, January 2nd. They issued an “outperform” rating and a $22.00 target price on the stock. Lake Street Capital set a $42.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, February 16th. Finally, BidaskClub raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 20th. Three analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $30.08.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ellington Management Group LLC acquired a new position in Heron Therapeutics in the 4th quarter valued at $195,000. Pinnacle Associates Ltd. acquired a new position in Heron Therapeutics in the 4th quarter valued at $201,000. Trexquant Investment LP acquired a new position in Heron Therapeutics in the 3rd quarter valued at $206,000. Jefferies Group LLC acquired a new position in Heron Therapeutics in the 4th quarter valued at $214,000. Finally, Jane Street Group LLC acquired a new position in Heron Therapeutics in the 3rd quarter valued at $223,000.
ILLEGAL ACTIVITY WARNING: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/17/heron-therapeutics-inc-hrtx-ceo-barry-d-quart-sells-100000-shares-of-stock.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.